Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study

Tsukasa Uno, Norio Yasui-Furukori, Mikiko Shimizu, Kazunobu Sugawara, Tomonori Tateishi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A new sensitive column-switching high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the simultaneous determination of rabeprazole, a proton pump inhibitor, and its active metabolite, rabeprazole thioether in human plasma. Rabeprazole, its thioether metabolite and 5-methyl-2-[{4-(3-methoxypropoxy)-3-methyl pyridin-2-yl} methyl sulfinyl]-1H-benzimidazole, as an internal standard were extracted from 1 ml of plasma using diethyl ether-dichloromethane (9:1, v/v) mixture and the extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm I.D.) for clean-up and column II (C18 Grand ODS-80TM TS analytical column, 5 μm, 250 mm × 4.6 mm I.D.) for separation. The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was ∼25 min. Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively. Intra- and inter-day coefficient variations were less than 6.5 and 4.5% for rabeprazole, 3.6 and 5.3% for rabeprazole thioether, respectively, at the different concentration ranges. The validated concentration ranges of this method were 1-1000 ng/ml for rabeprazole and 3-500 ng/ml for rabeprazole thioether. The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether. The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers.

Original languageEnglish
Pages (from-to)238-243
Number of pages6
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume824
Issue number1-2
DOIs
Publication statusPublished - 2005 Sep 25
Externally publishedYes

Fingerprint

Rabeprazole
Plasma (human)
Pharmacokinetics
High performance liquid chromatography
Metabolites
High Pressure Liquid Chromatography
Ultraviolet detectors
Drug Monitoring
Proton Pump Inhibitors
Methylene Chloride
Ether
rabeprazole-thioether
Volunteers
Plasmas
Recovery
Wavelength
Monitoring
Liquids
Pharmaceutical Preparations

Keywords

  • HPLC
  • Rabeprazole
  • Rabeprazole thioether

ASJC Scopus subject areas

  • Biochemistry

Cite this

Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study. / Uno, Tsukasa; Yasui-Furukori, Norio; Shimizu, Mikiko; Sugawara, Kazunobu; Tateishi, Tomonori.

In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 824, No. 1-2, 25.09.2005, p. 238-243.

Research output: Contribution to journalArticle

@article{9619cce535d44fb59e2f786417fbc5e0,
title = "Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study",
abstract = "A new sensitive column-switching high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the simultaneous determination of rabeprazole, a proton pump inhibitor, and its active metabolite, rabeprazole thioether in human plasma. Rabeprazole, its thioether metabolite and 5-methyl-2-[{4-(3-methoxypropoxy)-3-methyl pyridin-2-yl} methyl sulfinyl]-1H-benzimidazole, as an internal standard were extracted from 1 ml of plasma using diethyl ether-dichloromethane (9:1, v/v) mixture and the extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm I.D.) for clean-up and column II (C18 Grand ODS-80TM TS analytical column, 5 μm, 250 mm × 4.6 mm I.D.) for separation. The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was ∼25 min. Mean absolute recoveries were 78.0 and 88.3{\%} for rabeprazole and rabeprazole thioether, respectively. Intra- and inter-day coefficient variations were less than 6.5 and 4.5{\%} for rabeprazole, 3.6 and 5.3{\%} for rabeprazole thioether, respectively, at the different concentration ranges. The validated concentration ranges of this method were 1-1000 ng/ml for rabeprazole and 3-500 ng/ml for rabeprazole thioether. The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether. The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers.",
keywords = "HPLC, Rabeprazole, Rabeprazole thioether",
author = "Tsukasa Uno and Norio Yasui-Furukori and Mikiko Shimizu and Kazunobu Sugawara and Tomonori Tateishi",
year = "2005",
month = "9",
day = "25",
doi = "10.1016/j.jchromb.2005.07.027",
language = "English",
volume = "824",
pages = "238--243",
journal = "Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences",
issn = "1570-0232",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Determination of rabeprazole and its active metabolite, rabeprazole thioether in human plasma by column-switching high-performance liquid chromatography and its application to pharmacokinetic study

AU - Uno, Tsukasa

AU - Yasui-Furukori, Norio

AU - Shimizu, Mikiko

AU - Sugawara, Kazunobu

AU - Tateishi, Tomonori

PY - 2005/9/25

Y1 - 2005/9/25

N2 - A new sensitive column-switching high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the simultaneous determination of rabeprazole, a proton pump inhibitor, and its active metabolite, rabeprazole thioether in human plasma. Rabeprazole, its thioether metabolite and 5-methyl-2-[{4-(3-methoxypropoxy)-3-methyl pyridin-2-yl} methyl sulfinyl]-1H-benzimidazole, as an internal standard were extracted from 1 ml of plasma using diethyl ether-dichloromethane (9:1, v/v) mixture and the extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm I.D.) for clean-up and column II (C18 Grand ODS-80TM TS analytical column, 5 μm, 250 mm × 4.6 mm I.D.) for separation. The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was ∼25 min. Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively. Intra- and inter-day coefficient variations were less than 6.5 and 4.5% for rabeprazole, 3.6 and 5.3% for rabeprazole thioether, respectively, at the different concentration ranges. The validated concentration ranges of this method were 1-1000 ng/ml for rabeprazole and 3-500 ng/ml for rabeprazole thioether. The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether. The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers.

AB - A new sensitive column-switching high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the simultaneous determination of rabeprazole, a proton pump inhibitor, and its active metabolite, rabeprazole thioether in human plasma. Rabeprazole, its thioether metabolite and 5-methyl-2-[{4-(3-methoxypropoxy)-3-methyl pyridin-2-yl} methyl sulfinyl]-1H-benzimidazole, as an internal standard were extracted from 1 ml of plasma using diethyl ether-dichloromethane (9:1, v/v) mixture and the extract was injected into a column I (TSK-PW precolumn, 10 μm, 35 mm × 4.6 mm I.D.) for clean-up and column II (C18 Grand ODS-80TM TS analytical column, 5 μm, 250 mm × 4.6 mm I.D.) for separation. The peak was detected with an ultraviolet detector set at a wavelength of 288 nm, and the total time for chromatographic separation was ∼25 min. Mean absolute recoveries were 78.0 and 88.3% for rabeprazole and rabeprazole thioether, respectively. Intra- and inter-day coefficient variations were less than 6.5 and 4.5% for rabeprazole, 3.6 and 5.3% for rabeprazole thioether, respectively, at the different concentration ranges. The validated concentration ranges of this method were 1-1000 ng/ml for rabeprazole and 3-500 ng/ml for rabeprazole thioether. The limits of quantification were 1 ng/ml for rabeprazole and 3 ng/ml for rabeprazole thioether. The method was suitable for therapeutic drug monitoring and was applied to pharmacokinetic study in human volunteers.

KW - HPLC

KW - Rabeprazole

KW - Rabeprazole thioether

UR - http://www.scopus.com/inward/record.url?scp=24044525606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044525606&partnerID=8YFLogxK

U2 - 10.1016/j.jchromb.2005.07.027

DO - 10.1016/j.jchromb.2005.07.027

M3 - Article

VL - 824

SP - 238

EP - 243

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

SN - 1570-0232

IS - 1-2

ER -